Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise - Test2 - elhamkhani - TriplyDB

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

http://www.wikidata.org/entity/Q24657417

about

The imidazoline receptors and ligands in pain modulation The development of chronic pain: physiological CHANGE necessitates a multidisciplinary approach to treatment An integrated perspective on diabetic, alcoholic, and drug-induced neuropathy, etiology, and treatment in the US.Conditioned pain modulation is associated with common polymorphisms in the serotonin transporter gene Evidence and consensus recommendations for the pharmacological management of pain in India.Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions.Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy Effect of yoga on pain, brain-derived neurotrophic factor, and serotonin in premenopausal women with chronic low back pain.Pain and Anxiety versus Sense of Family Support in Lung Cancer Patients.The influence of depression, anxiety and somatization on the clinical symptoms and treatment response in patients with symptoms of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Combining opioid and adrenergic mechanisms for chronic pain.Burning through the pain: treatments for diabetic neuropathy.Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain Visceral pain and gastrointestinal microbiome.Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy.Baroreflex mechanisms in Irritable Bowel Syndrome: Part I. Traditional indices.Preventive Analgesic Efficacy of Nefopam in Acute and Chronic Pain After Breast Cancer Surgery: A Prospective, Double-Blind, and Randomized Trial The important role of CNS facilitation and inhibition for chronic pain.Duloxetine: a review of its use in the management of major depressive disorder in older adults.New approaches to the pharmacological management of generalized anxiety disorder.Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.Ketamine in pain management.Expert opinion on emerging drugs: chronic low back pain.Treatment of painful diabetic peripheral neuropathy.Managing comorbidities in patients with chronic heart failure: first, do no harm.A double-blind, placebo-controlled, parallel-group pilot study of milnacipran for chronic radicular pain (sciatica) associated with lumbosacral disc disease.Central sensitization in chronic low back pain: A narrative review.Asymmetries in reciprocal baroreflex mechanisms and chronic pain severity: Focusing on irritable bowel syndrome.A dual physiological character for cerebral mechanisms of sexuality and cognition: common somatic peripheral afferents.Thought suppression as a mediator of the association between depressed mood and prescription opioid craving among chronic pain patients.Open-label milnacipran for patients with persistent knee pain 1 year or longer after total knee arthroplasty: a pilot study.Attenuation of reserpine-induced pain/depression dyad by gentiopicroside through downregulation of GluN2B receptors in the amygdala of mice.High prevalence of restless legs syndrome among women with multi-site pain: a population-based study in Dalarna, Sweden.Musculoskeletal Pain in Melancholic and Atypical Depression.Development and pharmacological characterization of a model of sleep disruption-induced hypersensitivity in the rat.The plasticity of descending controls in pain: translational probing.Venlafaxine and oxycodone effects on human spinal and supraspinal pain processing: a randomized cross-over trial.A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia.Subliminal (latent) processing of pain and its evolution to conscious awareness.

P2860

Q26776329-4B1E9BD1-0975-4780-B98E-B01355C89136 Q26860844-B5D38CCE-2AEF-40D3-B6CC-31D1D73CC62C Q30236003-01A14C80-CB6A-4367-8B30-4ECE4D49AC11 Q30475971-43055495-68D8-4E3C-8F4C-17B92D8DA053 Q30844805-2A440D40-9159-4175-B87A-DABF9E48FF32 Q33583006-D9F625F5-3C29-4F3D-A2B9-6A9E15D30DFC Q33635965-3F9CF317-1B55-44FC-BE00-0302BAB06D50 Q33824509-6BF4A50E-C681-43E3-9E21-E720AECA23D1 Q33996696-E5636DFE-BEB5-47E8-A216-5C8CEAFA5FFB Q34003509-75F14014-B8C2-408B-BF37-22880F0F473B Q34030026-4F7DED98-2CB3-4FC5-9C8D-25584200EA88 Q34434307-2F6C71B0-7CB7-437E-B0A7-9458EB41DBC8 Q34485306-BD2D5E04-1CFB-4F37-9146-2D7C57830EF6 Q34999759-45943EDA-E279-4073-9464-F0F6B08299A3 Q35430488-2758B807-E098-4D58-8504-4D1336B69324 Q35565643-45AC606B-D618-4667-A95D-3E4283974852 Q36665104-1548B7B4-6C94-4F1B-A25E-036132EB5CD2 Q36993156-FBACC4B0-8A6B-46F0-9769-5E553B1D66A0 Q37523345-A0B721D9-29B4-4E7A-99E0-E319FFA38B48 Q38067355-956E0D69-5AB9-4AD8-A1CC-FEF403E83361 Q38071131-1E03E04B-1089-49EC-9D4F-4CE488A64624 Q38090730-D6EEC946-C223-46F0-8D27-70D7B57BB692 Q38105649-0EEA3950-55C0-4E6E-9C5A-0D05E6433401 Q38292223-5F275E18-B28A-4728-8FE9-58F4443B7045 Q38329620-C6F24400-ACA9-4315-92EB-076FE5A5D332 Q38402807-AB6F2736-95EB-4761-A1E2-E9879B2E0CC8 Q38416566-74137719-8C37-4FD2-AADE-D50BB67DF001 Q38803435-AECB222D-9569-434E-AABE-3441BEFA6107 Q39311712-FAA06F54-269B-4C58-8802-BB4051298C75 Q39761066-4F0F5479-D8A8-4FAD-8C59-C6B324F578DE Q40567117-3F278B99-3ADE-4F94-9F35-21E7DCFB9D4C Q42148416-71A38C0A-CB15-4E78-A6A0-24A599F073BF Q47794274-BF57FF95-62C5-4AB5-A479-C570A00F6BCB Q47893792-11BDDAF7-DA8E-409F-8815-B6CC9CD634DF Q47968136-271FE33B-D6CC-4B38-ACCB-88940FD92303 Q48032040-3B488F9E-D0A5-4785-9804-CB1405209E77 Q48305681-F7595385-AC17-42A3-AAAF-878B56420EB8 Q48476643-9B978397-48DA-4E59-8B1A-ABFC80F2A3BA Q52641632-BDBD4C68-0D80-4EFA-959C-5EFB17F1F580 Q55253332-EEDC3608-9362-41C7-96A8-BECCE780FF5B

P2860

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

http://www.wikidata.org/entity/Q24657417

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

@ast

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

@en

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

@nl

type

label

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

@ast

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

@en

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

@nl

prefLabel

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

@ast

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

@en

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

@nl

P1433

Q24657417-65E9B330-DF3F-44F2-8734-4B51FDB3C112

P1476

Q24657417-BFB6DBE9-908C-48E6-9829-42583AC408BE

P2093

Q24657417-0AAE6EE4-1FAA-4CD9-9E91-6C073AEB44E2

Q24657417-342C07E7-01B3-490F-ADC6-1DC5520C9946

Q24657417-804E4056-FCFB-4E41-A397-DCE6D31F02CC

Q24657417-8E41BA6A-6975-4250-B63B-530757E01FDC

Q24657417-B2BCC0F6-3025-474C-B9E5-4F97A15CDA9D

Q24657417-D9B48959-4B5B-4240-A069-0E1CE1068CD7

P2860

Q24657417-09EF6DC5-2A3A-4C6B-885C-F043A3A34CA4

Q24657417-0A07CAD5-5A1C-4A4B-A304-A41E075EF083

Q24657417-0FCFA485-E0C9-45F5-A010-18FDCC6B9779

Q24657417-11ABADF1-61A0-4EB1-BD4C-050A000840A3

Q24657417-122DD8E3-9073-4905-B664-62F40EA0ADC2

Q24657417-23FC634A-958C-4D97-B8C3-3981E6585C61

Q24657417-28F9B7C2-D27E-4434-99AE-A6E26246EEF3

Q24657417-3C0EBFE2-C8A9-4264-B600-727BD0D63016

Q24657417-3F1E1CCC-BC94-4F6D-9BC6-4BA8158A6A08

Q24657417-4334F720-9316-4FDB-8274-361492A55576

P304

Q24657417-FD4C6653-C16B-4D55-ACE6-100AC70FC12E

P31

Q24657417-D459A39B-9A8F-48F8-8F94-48FB0DB40645

P3181

Q24657417-4D5B2A39-A942-44FA-A316-2F0BC14C91A6

P356

Q24657417-2911AA17-4DBA-4E29-904B-9B903D46F14E

P407

Q24657417-1189EE22-241A-4A4D-86BF-47AF32C7BA1F

P433

Q24657417-C432842B-2EF0-4035-BDA2-81CF47BDCA65

P478

Q24657417-B9FA6005-0778-420E-B2BB-8F5DAD1B2A74

P577

Q24657417-61E2E3D3-61E7-405A-BD02-1FD7F96A3C00

P5875

Q24657417-2DD8D032-A7BA-43E3-AC8D-F980BC886F84

P698

Q24657417-05FE8900-D578-47B9-BF12-E7E9361FA710

P921

Q24657417-52c150cb-e688-439d-adb7-14a05163f6f1

Q24657417-64916db6-54d6-4035-a0ba-18f720dd76c0

P932

Q24657417-BB1AEDDC-26EB-44AB-936D-862498FD2FFF

P3181

P356

157015909790031201

P1433

Current Neuropharmacology

P1476

Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise

@en

P2093

Ashwin A Patkar

http://www.w3.org/2001/XMLSchema#string

Chi-Un Pae

http://www.w3.org/2001/XMLSchema#string

David M Marks

http://www.w3.org/2001/XMLSchema#string

Geun-Young Park

http://www.w3.org/2001/XMLSchema#string

Manan J Shah

http://www.w3.org/2001/XMLSchema#string

Prakash S Masand

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of fibromyalgia with antidepressants: a meta-analysis.

Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis.

Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression

Efficacy of milnacipran in patients with fibromyalgia.

Physiology of pain.

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Pain: neuroanatomy, chemical mediators, and clinical implications.

The molecular dynamics of pain control.

Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.

P304

331-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1941552

http://www.w3.org/2001/XMLSchema#string

P356

10.2174/157015909790031201

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44641286

http://www.w3.org/2001/XMLSchema#string

P698

20514212

http://www.w3.org/2001/XMLSchema#string

P921

P932

2811866

http://www.w3.org/2001/XMLSchema#string